OncWeekly

Your Front Row Seat to the Future of Cancer Care | Oncology News | Meeting Coverage | Clinical Trials |

[OncWeekly @OncWeekly]

G6PD inhibition leads to oxidative stress and cell death in tumors, boosting the efficacy of immunotherapies. #Oncology #CancerTreatment #G6PD - https://t.co/fTaCOesDF8

[OncWeekly @OncWeekly]

Patients with low G6PD expression have better outcomes with ICIs, suggesting a new therapeutic strategy. #CancerResearch #Immunotherapy #Oncology #LungCancer - https://t.co/fTaCOesDF8

[OncWeekly @OncWeekly]

SRS/FSR for CSM yields high CNN recovery rates and long-term tumor control, with SRS showing quicker improvements. #Oncology #CancerCare #RadiationOncology #OncWeekly - https://t.co/sUesBH3aOE

[OncWeekly @OncWeekly]

ML classifiers' accuracy in predicting PCR in breast cancer evaluated. #Oncology #CancerResearch #BreastCancer #MachineLearning #PrecisionOncology #OncWeekly - https://t.co/E1PDkBZ4nJ

[OncWeekly @OncWeekly]

Study shows low G6PD expression in tumors improves immune response and outcomes of immune checkpoint inhibitors. #CancerTreatment #Oncology #Immunotherapy #LungCancer #Melanoma - https://t.co/fTaCOesDF8

[OncWeekly @OncWeekly]

Upfront resection in elderly glioblastoma patients significantly improves survival rates. Key finding for treatment approaches. #CancerResearch #Glioblastoma #Oncology - https://t.co/vdTdWEb9Qw

[OncWeekly @OncWeekly]

Study: SRS/FSR for CSM shows significant CNNs recovery and excellent long-term radiological control. #Oncology #CancerResearch #Radiology #OncWeekly - https://t.co/sUesBH3aOE

[OncWeekly @OncWeekly]

Upfront resection improves survival in elderly glioblastoma patients, study reveals. https://t.co/vdTdWEb9Qw

[OncWeekly @OncWeekly]

Study shows COX-2 overexpression is linked to worse prognosis in breast cancer, correlated with TNM staging and histological grading. #BreastCancer #Oncology #COX2 - https://t.co/6qnVKBYDKJ

[OncWeekly @OncWeekly]

G6PD inhibition triggers immunogenic cell death, enhancing immunotherapy effectiveness against tumors. #CancerResearch #Immunotherapy #G6PD #Oncology #LungCancer #Melanoma - https://t.co/fTaCOesDF8

[OncWeekly @OncWeekly]

FDA reviews Immorta Bio's Senovax IND application for NSCLC. Potential breakthrough in lung cancer treatment on the horizon. #NSCLC #LungCancer #OncologyNews - https://t.co/DhkOscdqwB

[OncWeekly @OncWeekly]

Study compares ML classifiers for predicting PCR in breast cancer. #Oncology #CancerResearch #BreastCancer #MachineLearning #ClinicalTrials #OncWeekly - https://t.co/E1PDkBZ4nJ

[OncWeekly @OncWeekly]

SRS/FSR treatments for CSM lead to effective cranial nerve recovery and sustained tumor control. #CancerTreatment #Oncology #ClinicalTrials #OncWeekly - @ElbazTehila - https://t.co/sUesBH3aOE

[OncWeekly @OncWeekly]

Can ML improve PCR prediction in BC? Dive into the latest comparison of classifiers and find out! #Oncology #CancerResearch #BreastCancer #AIinMedicine #OncWeekly - https://t.co/E1PDkBZ4nJ

[OncWeekly @OncWeekly]

ICI + Antiangio-Ab leads in safety for NSCLC post-ICI failure. #Oncology #CancerResearch #OncWeekly - https://t.co/97eMUy9P4f

[OncWeekly @OncWeekly]

Study highlights potential of ARS model in LUAD treatment and prognosis. #Cancer #LungCancer #ClinicalTrials #OncWeekly https://t.co/GqHfq4aTjy

[OncWeekly @OncWeekly]

Improved survival in elderly glioblastoma patients through upfront resection. #CancerResearch #Glioblastoma #Oncology - https://t.co/vdTdWEb9Qw

[OncWeekly @OncWeekly]

Study: TKI + Chemo superior for PFS, ORR; ICI + TKI for OS in NSCLC post-ICI failure. #Cancer #OncWeekly - https://t.co/97eMUy9P4f

[OncWeekly @OncWeekly]

Elevated CKS1B in LUAD cells promotes growth and invasion. #CancerResearch #Oncology #ClinicalTrials #OncWeekly https://t.co/GqHfq4aTjy

[OncWeekly @OncWeekly]

CLINICAL TRIAL - Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) https://t.co/AMz26we9YV